Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
75.56
-0.22 (-0.29%)
At close: May 22, 2026, 4:00 PM EDT
76.06
+0.50 (0.66%)
After-hours: May 22, 2026, 5:31 PM EDT
Ionis Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 26 analysts polled by S&P Global, Ionis Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $100.92. The average 1-year stock price forecast is 33.56% higher than the current stock price, while the lowest is $47 (-37.80%) and the highest is $130 (+72.05%).
Price Target: $100.92 (+33.56%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Ionis Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 9 | 9 | 9 | 10 |
| Buy | 9 | 9 | 9 | 10 | 10 | 10 |
| Hold | 4 | 4 | 4 | 4 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 22 | 22 | 22 | 23 | 22 | 23 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Initiates $115 | Strong Buy | Initiates | $115 | +52.20% | May 19, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $95 → $100 | Buy | Maintains | $95 → $100 | +32.35% | Apr 30, 2026 |
| Barclays | Barclays | Buy Maintains $106 → $115 | Buy | Maintains | $106 → $115 | +52.20% | Apr 30, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $120 → $125 | Strong Buy | Maintains | $120 → $125 | +65.43% | Apr 30, 2026 |
| TD Cowen | TD Cowen | Strong Buy Maintains $110 → $108 | Strong Buy | Maintains | $110 → $108 | +42.93% | Apr 23, 2026 |
Financial Forecast
Revenue This Year
913.44M
from 943.71M
Decreased by -3.21%
Revenue Next Year
1.55B
from 913.44M
Increased by 69.47%
EPS This Year
-3.64
from -2.38
EPS Next Year
-1.49
from -3.64
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 994.4M | 2.2B | ||||||
| Avg | 913.4M | 1.5B | ||||||
| Low | 861.8M | 1.2B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 5.4% | 136.4% | ||||||
| Avg | -3.2% | 69.5% | ||||||
| Low | -8.7% | 31.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.72 | -0.07 | ||||||
| Avg | -3.64 | -1.49 | ||||||
| Low | -4.04 | -2.70 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.